Print  |  Close

Serum Tumor Marker Directed Disease Monitoring in Monitoring Patients with Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer


Active: Yes
Cancer Type: Breast Cancer NCT ID: NCT03723928
Trial Phases: Protocol IDs: S1703 (primary)
S1703
SWOG-S1703
NCI-2018-00090
Eligibility: 18 Years and older, Male and Female Study Type: Health services research
Study Sponsor: SWOG
NCI Full Details: http://clinicaltrials.gov/show/NCT03723928

Summary

This research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body (metastatic). Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

Objectives

PRIMARY OBJECTIVE:
I. To assess whether patients with HER-2 negative, hormone receptor positive, metastatic breast cancer who are monitored with serum tumor marker directed disease monitoring (STMDDM) have non-inferior overall survival compared to patients monitored with usual care.

SECONDARY OBJECTIVES:
I. To compare cumulative direct healthcare costs (in the United States) through 48 weeks among patients monitored with STMDDM versus those monitored with usual care in this patient population.
II. To assess whether the patient-reported outcomes (PROs) of anxiety and quality of life (QOL) are different among patients who are monitored with STMDDM compared with patients who are monitored with usual care in this patient population.

OTHER OBJECTIVES:
I. To assess modality and frequency of disease monitoring testing in the usual care cohort.
II. To assess the association of PROs and patient preferences for disease monitoring testing.
III. To evaluate predictors of physician preferences for disease monitoring testing.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients undergo imaging studies at a minimum frequency of every 12 weeks and continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.

ARM II: Patients undergo disease specific serum tumor marker (STM) evaluation every 4-8 weeks. Patients with elevated STM, undergo imaging evaluation. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.